Why Charles River Laboratories International, Inc. (CRL) Stock Rose 7.1% on Oct 5, 2026
What happened
Charles River Laboratories stock rose 4.62% to $303.59, driven by continued positive investor momentum following the company's recent Investor Day, where management raised its 2026 earnings outlook and projected 5–7% annual organic revenue growth through 2030 with targeted operating margins near 24% (finance.yahoo.com). The gain reflects analyst upgrades and stabilizing client bookings after a period of drug discovery project cancellations.
CRL earnings scheduled for November 4, 2026 (date not yet confirmed), with consensus EPS estimate of $2.97; monitor for updates on organic revenue growth trajectory and margin progress versus the newly raised 2030 targets.
Frequently asked questions
Why did Charles River Laboratories International, Inc. (CRL) stock rise on Oct 5, 2026?
Charles River Laboratories stock rose 4.62% to $303.59, driven by continued positive investor momentum following the company's recent Investor Day, where management raised its 2026 earnings outlook and projected 5–7% annual organic revenue growth through 2030 with targeted operating margins near 24% (finance.yahoo.com). The gain reflects analyst upgrades and stabilizing client bookings after a period of drug discovery project cancellations.
How much did CRL stock rise on Oct 5, 2026?
CRL rose 7.1% during the Oct 5, 2026 trading session.